ReviewMedicinal research reviews2026
Plasmepsins as Antimalarial Drug Targets-Then, Now, and the Future.
Review in Medicinal research reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Malaria is a devastating disease caused by Plasmodium parasites. Plasmodium parasites express ten cathepsin D-like aspartyl proteases, called plasmepsins (PMs). These PMs have diverse roles fulfill diverse functions throughout the parasite's lifecycle, though several exhibit functional redundancies. Among them, PMV, PMIV, and PMX are essential for asexual stage development, positioning them as prime candidates for antimalarial development. This review synthesizes current knowledge on PM biology and highlights the pivotal role of PM inhibitors in validating these proteases as therapeutic targets. Learnings from past research on PMs coupled with advances in experimental approaches have largely steered drug discovery efforts toward the development of dual PMIX/PMX inhibitors. Highlighted is an overview of the developmental trajectory of PM inhibitors, their progress to date, and their potential integration into future antimalarial therapies aimed at both prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.